Amedica reports positive study results & re-files FDA application for technology: 5 things to know

Salt Lake City-based Amedica Corp. reported positive study results, demonstrating rapid bone growth into porous silicon nitride.

Advertisement

Here are five things to know:

 

1. The study found the company’s porous silicone nitride promoted bone healing into the material four weeks post-implantation.

 

2. The porous silicone nitride utilized in the study was a cancellous-structured ceramic, which Amedica used in the center of its composite cervical implants.

 

3. Based on the favorable study results, Amedica re-filed an FDA application with a modified CsC-based cervical implant.

 

4. The CsC-based cervical implant is similar to Amedica’s ValeoC cervical implants.

 

5. Amedica hopes to launch its CsC technology platform in the U.S. market.

 

More articles on devices:
What Stryker CEO Kevin Lobo said on CNBC: 7 key quotes on healthcare, business & the future
Providence Medical Technology receives $10.5M new equity financing — 5 points
Stavros Vizirgianakis to lead Misonix as new president, CEO: 5 things to now

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.